title: Personalized radiotherapy: concepts, biomarkers and trial design.
abstract: In the past decade, and pointing onwards to the immediate future, clinical radiotherapy has undergone considerable developments, essentially including technological advances to sculpt radiation delivery, the demonstration of the benefit of adding concomitant cytotoxic agents to radiotherapy for a range of tumour types and, intriguingly, the increasing integration of targeted therapeutics for biological optimization of radiation effects. Recent molecular and imaging insights into radiobiology will provide a unique opportunity for rational patient treatment, enabling the parallel design of next-generation trials that formally examine the therapeutic outcome of adding targeted drugs to radiation, together with the critically important assessment of radiation volume and dose-limiting treatment toxicities. In considering the use of systemic agents with presumed radiosensitizing activity, this may also include the identification of molecular, metabolic and imaging markers of treatment response and tolerability, and will need particular attention on patient eligibility. In addition to providing an overview of clinical biomarker studies relevant for personalized radiotherapy, this communication will highlight principles in addressing clinical evaluation of combined-modality-targeted therapeutics and radiation. The increasing number of translational studies that bridge large-scale omics sciences with quality-assured phenomics end points-given the imperative development of open-source data repositories to allow investigators the access to the complex data sets-will enable radiation oncology to continue to position itself with the highest level of evidence within existing clinical practice.
authors.affiliation: 1 Department of Oncology, Akershus University Hospital, Lørenskog, Norway.|2 Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
authors.forename: A H
authors.initials: AH
authors.lastname: Ree
authors.affiliation: 1 Department of Oncology, Akershus University Hospital, Lørenskog, Norway.
authors.forename: K R
authors.initials: KR
authors.lastname: Redalen
mesh_terms: D014408:Biomarkers, Tumor; D059248:Chemoradiotherapy; D002986:Clinical Trials as Topic; D004249:DNA Damage; D004260:DNA Repair; D020000:Decision Support Systems, Clinical; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy*; D061214:Patient Safety; D057285:Precision Medicine; D011878:Radiotherapy / Q000009:adverse effects; D012004:Rectal Neoplasms / Q000532:radiotherapy; D012107:Research Design
chemical_list: D014408:Biomarkers, Tumor